ClinicalTrials.gg
CompletedNCT02443623Updated Mar 18, 2024Results posted

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

A Phase 4 interventional study of Vaccination with ACAM2000 in Smallpox Vaccine Adverse Reaction, sponsored by Emergent BioSolutions. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Emergent BioSolutions · Phase 4, Interventional, and Basic science

Phase
Phase 4
Study type
Interventional
Enrollment
3,032
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Objectives:

  • To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
  • To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Read the detailed description

This protocol is being conducted to vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). The objective of this protocol is to ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.

Participants will be followed for the duration of the study, an expected average of 90 days as described below in the planned study assessments.

Screening [complete within 14 days before Baseline (Day 0)]:

  • Informed consent obtained from prospective donors
  • Post-consent information including medical history, smallpox vaccination history, current medications, detailed demographics, BMI, physical exam, vital signs, and assessment for pericarditis/myocarditis symptoms, blood samples will be collected and a baseline EKG (if applicable).

Baseline (Day 0) prior to vaccination:

-Physical exam and vital signs, urine pregnancy test for all female subjects of child-bearing potential, current medications, assessment for pericarditis/myocarditis.

Baseline (Day 0) vaccination and post-vaccination:

-Vaccination with ACAM2000, vaccination site inspection 30 post-vaccination, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.

Post-vaccination Day 3 (±1):

-Assessment for pericarditis/myocarditis, vaccination site inspection, unanticipated problems, unexpected and serious adverse reactions or complications post-vaccination, all adverse events including all cardiovascular adverse events (symptoms and signs).

Post-vaccination Day 7 (±1):

-Assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.

Post-vaccination Day 12 (±2), 21 (±3), and 28 (±3):

-Assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.

End of study post-vaccination Day 35 (±3) or Early Withdrawal:

Vital signs, assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.

Final Safety Assessment Day 90 (±3):

Assessment for pericarditis/myocarditis, unanticipated problems, unexpected and serious adverse reactions or complications post-vaccination, all adverse events including all cardiovascular adverse events (symptoms and signs).

02

Conditions studied

  • Smallpox Vaccine Adverse Reaction

Browse trials for

03

In context

Smallpox

73 studies on the registry are indexed under Smallpox; 5 are open to participants now.

This study's enrollment of 3,032 is above the median of 150 across 61 interventional studies indexed under Smallpox.

Browse Smallpox studies →

Lead sponsor

Emergent BioSolutions is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written .
  • Age 18 to 65.
  • Normal and healthy (immune competent) as determined by medical history, physical exam, vital signs and clinical laboratory tests during the screening period.
  • If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process.
  • Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.
  • Negative serology during screening period.
  • Subject must have been previously immunized for smallpox, at ≥3 years prior to commencement of screening assessments, and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination scar.

Exclusion criteria

Exclusion Criteria:

  • History of severe related adverse event(s) from previous participation in VA-001 or VA-006 trials or to any smallpox vaccination.
  • The subject, or a household contact or other close/intimate contact of the subject has ANY of the following:

    • Eczema, history of eczema, exfoliative skin conditions, wounds, burns, or other skin conditions at the investigator's discretion.
    • A history of immunodeficiency.
    • Currently or has recently received radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH), , or drugs.
    • Eye disease treated with topical steroids.
    • Known or suspected disorders of immunoglobulin synthesis.
    • Leukemia, lymphomas of any type, melanoma, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
    • Has been diagnosed with cancer and who will be undergoing chemotherapy or radiation therapy during the vaccination healing time.
    • Is a transplant recipient (except for corneal transplant).
    • Is pregnant, planning pregnancy or breast feeding (female subjects of must have negative pregnancy test prior to vaccination). Women of child-bearing potential (WOCBP) are temporarily excluded due to COVID.
  • Household or other close/intimate contact(s) under the age of 12 months.
  • History of allergies to phenol, any of the antibiotics listed in the vaccine content, or any other component of ACAM2000 or its diluents.
  • Subjects with kidney disease (except kidney stones).
  • Subjects with abnormal at screening (if applicable). To mitigate the risk of enrolling at risk subjects and potentially jeopardizing subject safety an EKG will be performed prior to vaccination with ACAM2000 smallpox vaccine in all potential subjects ≥50 years old and for all potential subjects \<50 with two cardiac risk factors as listed immediately below including; severely or morbidly obese or higher obesity classification ( ≥36); high blood pressure; high blood cholesterol; diabetes or high blood sugar; a first degree relative who had a heart condition before the age of 50; and current tobacco smokers.
  • Subject has three or more of the following risk factors:

    • Severely or morbidly obese or higher obesity classification (BMI ≥36)
    • High blood pressure diagnosed by a doctor
    • High blood cholesterol diagnosed by a doctor
    • Diabetes or high blood sugar diagnosed by a doctor
    • A first degree relative (for example, mother, father, brother, sister) who had a heart condition before the age of 50
    • Currently smokes tobacco (cigarettes)
  • Cardiovascular disease or heart condition diagnosed by a doctor at any time in the past, with or without symptoms, including:

    • Arrhythmia
    • Syncope related to cardiac disease
    • Previous myocardial infarction
    • Angina
    • Coronary artery disease
    • Congestive heart failure
    • Cardiomyopathy
    • Stroke or
    • Myocarditis
    • Pericarditis
    • Chest pain or shortness of breath with activity (such as climbing stairs), peripheral edema, heart palpitations, dry cough, irregular heartbeat, excessive fatigue, unexplained syncope
    • Other heart conditions being treated by a physician
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,032 participants (actual)

Study arms

  • Experimental
    Single Arm Vaccinated with ACAM2000

    * To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). * To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.

    Biological: Vaccination with ACAM2000

Interventions

  • BiologicalVaccination with ACAM2000

    Drug page: ACAM2000

    In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.

06

What researchers measure

Primary outcomes

  1. Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)

    Number of subjects with AEs including SAEs up to 90 days after vaccination.

    Time frame: Adverse event data was collected from vaccinated participants through Day 90.

  2. Number of Vaccinated Participants With Related Adverse Events

    Number of subjects with related AEs up to 90 days after vaccination.

    Time frame: Adverse event data was collected from vaccinated participants through Day 90.

  3. Number of Vaccinated Participants With Serious Adverse Events (SAEs)

    Number of subjects with SAEs up to 90 days after vaccination.

    Time frame: Adverse event data was collected from vaccinated participants through Day 90.

07

Results

Posted Oct 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneSingle Arm Vaccinated With ACAM2000
Started3032
Completed2788
Not completed244

Outcome measures

PrimaryNumber of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)

Number of subjects with AEs including SAEs up to 90 days after vaccination.

Time frame:
Adverse event data was collected from vaccinated participants through Day 90.
Reported as:
Count of participants · Participants
Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)
ParticipantsSingle Arm Vaccinated With ACAM2000
Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)1420
PrimaryNumber of Vaccinated Participants With Related Adverse Events

Number of subjects with related AEs up to 90 days after vaccination.

Time frame:
Adverse event data was collected from vaccinated participants through Day 90.
Reported as:
Count of participants · Participants
Number of Vaccinated Participants With Related Adverse Events
ParticipantsSingle Arm Vaccinated With ACAM2000
Number of Vaccinated Participants With Related Adverse Events1190
PrimaryNumber of Vaccinated Participants With Serious Adverse Events (SAEs)

Number of subjects with SAEs up to 90 days after vaccination.

Time frame:
Adverse event data was collected from vaccinated participants through Day 90.
Reported as:
Count of participants · Participants
Number of Vaccinated Participants With Serious Adverse Events (SAEs)
ParticipantsSingle Arm Vaccinated With ACAM2000
Number of Vaccinated Participants With Serious Adverse Events (SAEs)25

Adverse events

Collected over Adverse event data was collected from vaccinated participants through Day 90.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm Vaccinated With ACAM2000 With AEs1/3,032 (0%)25/3,032 (0.8%)1,413/3,032 (46.6%)
Single Arm Vaccinated With ACAM2000 With Related AEs——1,190/3,032 (39.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventSingle Arm Vaccinated With ACAM2000 With AEsSingle Arm Vaccinated With ACAM2000 With Related AEs
Chest painGeneral disorders2/3032—
Non-cardiac chest painGeneral disorders2/3032—
PneumothoraxRespiratory, thoracic and mediastinal disorders2/3032—
Acute coronary syndromeCardiac disorders1/3032—
Acute myocardial infarctionCardiac disorders1/3032—
Angina pectorisCardiac disorders1/3032—
HypersensitivityImmune system disorders1/3032—
AppendicitisInfections and infestations1/3032—
Peritonsillar abscessInfections and infestations1/3032—
Post vaccination autoinoculationInfections and infestations1/3032—
Most frequent other events
Showing 10 of 248
Most frequent other events
EventSingle Arm Vaccinated With ACAM2000 With AEsSingle Arm Vaccinated With ACAM2000 With Related AEs
Vaccination site scabGeneral disorders1098/30321089/3032
HeadacheNervous system disorders182/303258/3032
PyrexiaGeneral disorders56/303232/3032
FatigueGeneral disorders48/303215/3032
Vaccination site painGeneral disorders46/303243/3032
CoughRespiratory, thoracic and mediastinal disorders45/30327/3032
NauseaGastrointestinal disorders34/30328/3032
DiarrheaGastrointestinal disorders24/30323/3032
PainGeneral disorders23/303211/3032
Vaccination site pruritusGeneral disorders22/303221/3032

Baseline characteristics

The safety population consisted of 3032 participants who were vaccinated, including 208 participants who were vaccinated twice (n= 208 includes two participants who were inadvertently vaccinated twice were included twice in demography and all participant counts).

Age, Categorical
Age, Categorical(Participants)Single Arm Vaccinated With ACAM2000
<=18 years1
Between 18 and 65 years3013
>=65 years18
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm Vaccinated With ACAM2000
Female765
Male2267
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm Vaccinated With ACAM2000
Hispanic or Latino626
Not Hispanic or Latino2325
Unknown or Not Reported81
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm Vaccinated With ACAM2000
American Indian or Alaska Native64
Asian25
Native Hawaiian or Other Pacific Islander13
Black or African American744
White2123
More than one race27
Unknown or Not Reported36
Region of Enrollment
Region of Enrollment(participants)Single Arm Vaccinated With ACAM2000
United States3032
Height
Height(cm)Single Arm Vaccinated With ACAM2000
Mean174.3 ± 9.5
Weight
Weight(kg)Single Arm Vaccinated With ACAM2000
Mean92.5 ± 20.4
BMI
BMI(kg/m^2)Single Arm Vaccinated With ACAM2000
Mean30.4 ± 6.4
08

Study locations

1 site
  • Bio Products Laboratory Ltd (plasma vendor of Emergent BioSolutions)
    Winnipeg, Manitoba R3T 5Y3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Jul 2021 and a completion of Aug 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2015
First posted
May 14, 2015
Start
Sep 2015
Primary completionActual
Jul 2021
CompletionActual
Aug 2021
Results first posted
Oct 26, 2022
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02443623
Responsible party
Sponsor
First posted
May 14, 2015
Start date
Sep 2015
Primary completion
Jul 2021
Completion
Aug 2021
Results posted
Oct 26, 2022
Last update
Mar 18, 2024

Study contacts

Christine Hall, PhD
study director · Emergent BioSolutions

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ACAM2000

Start the discussion